Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director · CEO AND PRESIDENT | March 20, 2024 | March 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date March 20, 2024 · Filed March 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2034-03-20 | Direct | 455,000 |
Reported balance
After 2024-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-20 · Grant · Acquired 455,000 · Balance 455,000 F1: 25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2024 Filed Mar 22, 2024 17:00 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 455,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001415889-24-008973 · form4-03222024_050307.xml · derivative · entry 1 TRENARY C RUSSELL III · CIK 0001227307 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 17:40 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 257,143 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-024879 · doc4.xml · derivative · entry 1 TRENARY C RUSSELL III · CIK 0001227307 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,143 Underlying: Common Stock · 257,143 shares Expires 2033-04-17 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 17:07 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 19,925 | $1.06 | $21,120.50 |
DisclosureSEC source: 0001209191-22-038985 · doc4.xml · nonDerivative · entry 1 TRENARY C RUSSELL III · CIK 0001227307 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,925 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.03 to $1.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:44 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-22-022669 · doc4.xml · derivative · entry 1 TRENARY C RUSSELL III · CIK 0001227307 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-12-21 F1 · shares: Represents the number of shares that vested under a performance-based stock option grant based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the option, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 31, 2022. The vested shares represents the first of four possible vesting events of the total number of shares subject to the option. The remaining shares subject to the option will vest only upon the satisfaction of additional performance vesting criteria. F2 · derivative.exercise_date: Fully vested and immediately exercisable. Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 17:27 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 25,000 | $1.39 | $34,750.00 |
DisclosureSEC source: 0001209191-21-068137 · doc4.xml · nonDerivative · entry 1 TRENARY C RUSSELL III · CIK 0001227307 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.37 to $1.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 17:07 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $1.40 | $14,000.00 |
DisclosureSEC source: 0001209191-21-067644 · doc4.xml · nonDerivative · entry 1 TRENARY C RUSSELL III · CIK 0001227307 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 17:26 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 4,000,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-21-046011 · doc4.xml · derivative · entry 1 TRENARY C RUSSELL III · CIK 0001227307 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2031-07-06 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on July 6, 2022, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.